You are not logged in.
Openly accessible

Neurobehavioral burden of multiple sclerosis with nanotheranostics

Sriramoju, Bhasker, Kanwar, Rupinder K. and Kanwar, Jagat R. 2015, Neurobehavioral burden of multiple sclerosis with nanotheranostics, Neuropsychiatric disease and treatment, vol. 11, pp. 2675-2689, doi: 10.2147/NDT.S82768.

Attached Files
Name Description MIMEType Size Downloads
sriramoju-neurobehaviouralburden-2015.pdf Published version application/pdf 1.49MB 5

Title Neurobehavioral burden of multiple sclerosis with nanotheranostics
Author(s) Sriramoju, Bhasker
Kanwar, Rupinder K.
Kanwar, Jagat R.
Journal name Neuropsychiatric disease and treatment
Volume number 11
Start page 2675
End page 2689
Total pages 15
Publisher Dove Medical Press
Place of publication Auckland, New Zealand
Publication date 2015-10-15
ISSN 1176-6328
Keyword(s) behavioral disorders
behavioral tests
demyelination
Science & Technology
Life Sciences & Biomedicine
Clinical Neurology
Psychiatry
Neurosciences & Neurology
EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS
STEM-CELL TRANSPLANTATION
PITUITARY-ADRENAL AXIS
CENTRAL-NERVOUS-SYSTEM
IN-VIVO
COGNITIVE IMPAIRMENT
INTERFERON BETA-1A
PSYCHIATRIC MORBIDITY
DEPRESSIVE SYMPTOMS
CEREBROSPINAL-FLUID
Summary Multiple sclerosis (MS) is a chronic demyelinating neurological disorder affecting people worldwide; women are affected more than men. MS results in serious neurological deficits along with behavioral compromise, the mechanisms of which still remain unclear. Behavioral disturbances such as depression, anxiety, cognitive impairment, psychosis, euphoria, sleep disturbances, and fatigue affect the quality of life in MS patients. Among these, depression and psychosis are more common than any other neurological disorders. In addition, depression is associated with other comorbidities. Although anxiety is often misdiagnosed in MS patients, it can induce suicidal ideation if it coexists with depression. An interrelation between sleep abnormalities and fatigue is also reported among MS patients. In addition, therapeutics for MS is always a challenge because of the presence of the blood-brain barrier, adding to the lack of detailed understanding of the disease pathology. In this review, we tried to summarize various behavioral pathologies and their association with MS, followed by its conventional treatment and nanotheranostics.
Language eng
DOI 10.2147/NDT.S82768
Field of Research 1103 Clinical Sciences
1109 Neurosciences
119999 Medical and Health Sciences not elsewhere classified
Socio Economic Objective 920299 Health and Support Services not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2015, The Authors
Free to Read? Yes
Use Rights Creative Commons Attribution non-commercial licence
Persistent URL http://hdl.handle.net/10536/DRO/DU:30080173

Document type: Journal Article
Collections: School of Medicine
Open Access Collection
Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in TR Web of Science
Scopus Citation Count Cited 2 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 80 Abstract Views, 6 File Downloads  -  Detailed Statistics
Created: Wed, 09 Dec 2015, 13:28:30 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.